In normal immunologic function, the body appropriately balances cAMP-regulated pathways. However, UC investigators have found that when cAMP levels in dendritic cells are too low or too high, there is a bias, respectively, toward either Th2 or Th17 response and the immunopathologies associated with each pathway.
Studies in cAMP-deficient mice (GNASCD11c KO mice) have led to an understanding of how drugs under development (i.e., Gαs and Gαi agonists and antagonist) may be used for the treatment of inflammatory diseases. GNAI2CD11c KO mice will be available by early 2016.
Based on the finding that cAMP levels in dendritic cells maintain the balance between Th2 and Th17 activation:
Application and development of this over-arching model of how Th2 and Th17 are regulated may clarify cellular and the molecular mechanisms which toggle between appropriate and inappropriate Th2 and Th17 responses thereby enabling the development of novel therapeutics for patients.
In vitro and in vivo studies have identified the relevant cells and the pathway by which low cAMP levels in dendritic cells provokes an excessive Th2 immune responses and allergic eosinophilic bronchial asthma whereas high cAMP levels in dendritic cells provokes excessive Th17 responses and neutrophilic asthma.
US rights available for licensure. See “Patent Status”, below.
Country | Type | Number | Dated | Case |
United States Of America | Published Application | 2014059147 | 04/17/2014 | 2011-208 |
cAMP, dendritic cell, Th2, Th-2, Th17, Th-17, immunopathologies, immunopathology, Gas, GaI, agonists, agonism, antagonist, antagonism, inflammatory, inflammation, asthma, rhinitis, dermatitis, allergy, allergies, Crohn’s disease, multiple sclerosis, MS, C